CMS unveils new Medicaid drug payment model

FDA says it raised concerns about Biohaven’s ataxia study several times since it was proposed

The FDA told Biohaven its study using real-world data “would likely be inadequate to provide substantial evidence of effectiveness” when it was proposed, according to

Gilead’s Trodelvy fails Phase 3 breast cancer study

Gilead’s Trodelvy failed to meet the primary endpoint in a Phase 3 trial for certain breast cancer patients, marking another setback for a key drug

#SITC25: Akeso, Summit’s PD-1xVEGF drug extends life in China lung cancer study

Researchers reported that adding Akeso and Summit Therapeutics’ ivonescimab to chemotherapy cut the risk of death by 26% in a study conducted in China for

Sana suspends work on allogeneic CAR-T; Biokin eyes $387M raise in Hong Kong

Plus, news about Codexis, Gilead, nChroma Bio, Bavarian Nordic, UroGen, Agenus, Accipiter Biosciences and Immunocore: ✂️ Sana trims cell therapy pipeline: The Seattle-based biotech is

ObesityWeek rode the waves of the field’s most dramatic week in months

ATLANTA — At one of the main annual gatherings of researchers and drug developers in the obesity field, Novo Nordisk and Eli Lilly were the